Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceBrain & cognition

Agmatine Sulfate

Agmatine has an interesting pharmacology — NMDA antagonism, nitric oxide modulation, imidazoline receptor activity — and a genuinely encouraging small trial in nerve-related back pain. Beyond that, almost everything sold on the label is extrapolated from rodents, and the pump-and-nootropic claims have no human trials at all.

What the science says

  • Reducing neuropathic and radicular pain Moderate evidence

    Keynan's 2010 study, an open-label dose-escalation phase followed by a randomised double-blind placebo-controlled trial, found 2.67 g/day of dietary agmatine sulfate for 14 days improved pain and quality-of-life scores in patients with lumbar disc-associated radiculopathy. This is the single best human trial of agmatine, but it is small and has not been independently replicated.

  • Cardiovascular effects Limited evidence

    A 2025 systematic review of agmatine's cardiovascular impacts found effects on blood pressure regulation, endothelial function and cardioprotection, but the evidence base is dominated by animal and in vitro work with very little controlled human data. Nothing here supports self-treatment for cardiovascular conditions.

  • Enhancing muscle pump and vasodilation Limited evidence

    This is the main pre-workout marketing claim and it has essentially no human evidence. Agmatine modulates nitric oxide synthase in complex ways — it inhibits some isoforms — so a straightforward vasodilatory "pump" effect is not even mechanistically clear-cut.

  • Mood, anxiety and depression Limited evidence

    Rodent models consistently show antidepressant- and anxiolytic-like effects, and there are open-label case reports in treatment-resistant depression. No randomised controlled trial in humans exists, so this remains a hypothesis rather than a finding.

Dosage & safety

Studied doseThe radiculopathy trial used 2.67 g/day of agmatine sulfate for 14 days. Consumer pre-workouts typically contain 500-1000 mg, a dose with no supporting human data. There is no established long-term dosing.
SafetyShort-term human data (up to a few weeks at 2.67 g/day) report mild GI effects including diarrhoea and nausea; longer-term safety in humans is unknown. Agmatine can lower blood pressure and blood glucose, so caution is warranted with antihypertensives and antidiabetic drugs. Because it is an NMDA receptor antagonist and modulates monoamines, avoid combining with antidepressants, particularly MAOIs, without medical advice. Avoid in pregnancy and breastfeeding. Regulatory status is inconsistent: agmatine is not an approved novel food in the EU and its sale as a supplement is restricted in several jurisdictions, including Australia and Canada. Not currently on the WADA prohibited list.

Scientific references

Where to buy

California Gold Nutrition, Agmatine Sulfate, 750 mg, 120 Veggie Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Brain & cognition